Search research articles
Contact Us
Filters
Showing results (751-760 of 993) with videos related to
Page
of 100
Sort By:
Plos Medicine
|
July 3, 2019
Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network
Andrée-Anne Grosset, Véronique Ouellet, Christine Caron, et al.
World Journal of Urology
|
March 5, 2025
The effect of chronic kidney disease on adverse in-hospital outcomes after radical cystectomy with ileal conduit urinary diversion
Michele Nicolazzini, Natali Rodriguez Peñaranda, Fabian Falkenbach, et al.
Urologic Oncology
|
October 18, 2024
Neoadjuvant chemotherapy before radical cystectomy in patients with organ-confined and non-organ-confined urothelial carcinoma
Mario de Angelis, Letizia Maria Ippolita Jannello, Carolin Siech, et al.
Journal of Racial and Ethnic Health Disparities
|
August 19, 2024
Race/Ethnicity Affects Access and Survival Differences After Neoadjuvant or Adjuvant Chemotherapy at Radical Cystectomy in Urothelial Carcinoma Patients
Mario de Angelis, Letizia Maria Ippolita Jannello, Carolin Siech, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 11, 2013
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer
M Dror Michaelson, Stephane Oudard, Yen-Chuan Ou, et al.
Urologic Oncology
|
January 14, 2014
Effect of body mass index on the outcomes of patients with upper and lower urinary tract cancers treated by radical surgery: results from a Canadian multicenter collaboration
Bassel G Bachir, Armen G Aprikian, Jonathan I Izawa, et al.
BJU International
|
March 18, 2024
Trimodal therapy effect on survival in urothelial vs non-urothelial bladder cancer
Mario de Angelis, Andrea Baudo, Carolin Siech, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2015
Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5
Karim Fizazi, Robert Jones, Stephane Oudard, et al.
European Urology Focus
|
August 21, 2025
Life Expectancy of Renal Cell Carcinoma with Variant Histology
Quynh Chi Le, Andrea Marmiroli, Mattia Longoni, et al.
Seminars in Oncology
|
November 4, 2022
IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: A structured systematic review over time
Benedikt Hoeh, Rocco Simone Flammia, Lukas Hohenhorst, et al.
Page
of 100
Search research articles
Search
Showing results (751-760 of 993) with videos related to
Sort By:
Page
of 100
Plos Medicine
|
July 3, 2019
Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network
Andrée-Anne Grosset, Véronique Ouellet, Christine Caron, et al.
World Journal of Urology
|
March 5, 2025
The effect of chronic kidney disease on adverse in-hospital outcomes after radical cystectomy with ileal conduit urinary diversion
Michele Nicolazzini, Natali Rodriguez Peñaranda, Fabian Falkenbach, et al.
Urologic Oncology
|
October 18, 2024
Neoadjuvant chemotherapy before radical cystectomy in patients with organ-confined and non-organ-confined urothelial carcinoma
Mario de Angelis, Letizia Maria Ippolita Jannello, Carolin Siech, et al.
Journal of Racial and Ethnic Health Disparities
|
August 19, 2024
Race/Ethnicity Affects Access and Survival Differences After Neoadjuvant or Adjuvant Chemotherapy at Radical Cystectomy in Urothelial Carcinoma Patients
Mario de Angelis, Letizia Maria Ippolita Jannello, Carolin Siech, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 11, 2013
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer
M Dror Michaelson, Stephane Oudard, Yen-Chuan Ou, et al.
Urologic Oncology
|
January 14, 2014
Effect of body mass index on the outcomes of patients with upper and lower urinary tract cancers treated by radical surgery: results from a Canadian multicenter collaboration
Bassel G Bachir, Armen G Aprikian, Jonathan I Izawa, et al.
BJU International
|
March 18, 2024
Trimodal therapy effect on survival in urothelial vs non-urothelial bladder cancer
Mario de Angelis, Andrea Baudo, Carolin Siech, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2015
Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5
Karim Fizazi, Robert Jones, Stephane Oudard, et al.
European Urology Focus
|
August 21, 2025
Life Expectancy of Renal Cell Carcinoma with Variant Histology
Quynh Chi Le, Andrea Marmiroli, Mattia Longoni, et al.
Seminars in Oncology
|
November 4, 2022
IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: A structured systematic review over time
Benedikt Hoeh, Rocco Simone Flammia, Lukas Hohenhorst, et al.
Page
of 100